1. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. Issue 7 (1st March 2021) Authors: Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Wei, Yu-Cheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Sheng-Xiang; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu Journal: Journal of clinical oncology Issue: Volume 39:Issue 7(2021) Page Start: 713 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Issue 1 (January 2018) Authors: Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Issue 1 (January 2018) Authors: Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study. (December 2020) Authors: Zeng, Jian; Mao, Wei-Min; Chen, Qi-Xun; Luo, Tao-Bo; Wu, Yi-Long; Zhou, Qing; Yang, Xue-Ning; Yan, Hong-Hong; Zhong, Wen-Zhao; Wang, Qun; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei Journal: Lung cancer Issue: Volume 150(2020) Page Start: 164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The role of Ag, Ca, Zr and Al in strengthening effects of ZK series alloys by altering G.P. zones stability. (1st April 2018) Authors: Ma, Hai-Tao; Yuan, Rong; Xie, Yao-Ping; Gao, Hui; Hu, Li-Juan; Li, Xiao-Di; Qian, Yi-Chen; Dai, Zhong-Hai Journal: Acta materialia Issue: Volume 147(2018) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The Zhangjiatun igneous complex in the southeastern margin of the Central Asian Orogenic Belt, NE China: Evidence for an Early Paleozoic intra-oceanic arc. (1st June 2020) Authors: Ma, Hai-Tao; Ma, Xu; Chen, Jia-Fu; Chen, Bin; Li, Chao; Zhou, Li-Min; Yang, Hong-Zhang Journal: Journal of Asian earth sciences Issue: Volume 194(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗